Acadia Pharmaceuticals

Acadia Pharmaceuticals Inc. is a biopharmaceutical company based in San Diego, California, specializing in neuroscience. The company develops and commercializes innovative therapies for central nervous system (CNS) disorders. With additional operations in Princeton, New Jersey, and international offices in Denmark, Switzerland, and the UK, Acadia employs over 500 professionals dedicated to addressing unmet medical needs in neurological and psychiatric conditions. Founded in 1993 and publicly traded since 2004, Acadia is known for its FDA-approved treatment, Nuplazid (pimavanserin), which addresses hallucinations and delusions associated with Parkinson’s disease psychosis. The company is also advancing its pipeline with investigations into schizophrenia, major depressive disorder, and dementia-related psychosis, as well as developing Trofinetide for Rett Syndrome. Acadia focuses on small-molecule drug discovery and emphasizes non-dopaminergic mechanisms to enhance safety and tolerability in its treatments.